Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Fig. 1

In-vivo stability of of [177Lu]Lu-PP-F11N. Representative HPLC chromatograms obtained from blood stability studies of patient 7. These chromatograms serve as illustrative examples. A direct comparison of the chromatograms at each time point reveals a notably higher percentage of intact peptide following premedication with Entresto®. Blue line: with Entresto®, red line: without Entresto®

Back to article page